Bioxytran (BIXT) Emerging Growth Conference 79 summary

Key technology platforms and clinical progress

• Three platform technologies: broad-spectrum oral antiviral, oxygenation molecule for stroke, and cancer metastasis treatment, all developed using AI.

• Oral antiviral achieved 100% viral reduction in seven days in clinical trials, with ongoing dose optimization and plans for a registrational trial in India.

• Oxygenation molecule, supported by an FDA-approved device, offers a potential alternative to hyperbaric oxygen therapy, delivering the equivalent of 18 hours of HBOT in a single injection.

• Cancer platform targets metastasis and fibrosis, with combination therapy potential to enhance checkpoint inhibitors like Keytruda.

• Universal oxygen carrier demonstrated survival benefits in animal models and is being discussed with government agencies.

Market opportunity and investment highlights

• Disrupting a $55.36 billion global antiviral market with a broad-spectrum antiviral that covers multiple virus families and has patent coverage for 60 viruses.

• Company trades at an $8 million market cap, significantly lower than peers, with a thin float and active licensing discussions.

• Management is targeting partnerships with major pharmaceutical companies, especially those needing galectin-3 blockers for oncology.

• Strategic relationships are being pursued for bird flu and other high-need viral indications.

Scientific rationale and clinical evidence

• Galectins are central to chronic diseases, viral adhesion, cancer progression, and fibrosis; blocking galectins disrupts these disease processes.

• Clinical data show rapid viral clearance, symptom resolution, and no viral rebound compared to standard treatments like Paxlovid.

• Combination therapy with galectin antagonists can double response rates in cancer compared to standard of care.

• Animal studies with the universal oxygen carrier show increased tissue oxygenation and survival even after severe blood loss.